Moderna has developed a new and improved version of its COVID-19 vaccine, called mRNA-1283. This new vaccine is more targeted than the original, and it has shown promise in early clinical trials.
mRNA-1283 is a bivalent vaccine, meaning that it targets two different parts of the SARS-CoV-2 virus: the N-terminal domain (NTD) and the receptor binding domain (RBD). The NTD is the part of the virus that helps it to attach to host cells, and the RBD is the part of the virus that binds to the ACE2 receptor on human cells.
In a preclinical study, mRNA-1283 was shown to produce strong neutralizing antibody responses against a variety of SARS-CoV-2 variants, including Omicron. The vaccine was also well-tolerated, with no serious side effects reported.
Moderna has now begun a Phase 1 clinical trial of mRNA-1283 in healthy adults. The trial is designed to assess the safety and immunogenicity of the vaccine. If the trial is successful, Moderna plans to begin Phase 2 and Phase 3 trials in the coming months.
The development of mRNA-1283 is a significant step forward in the fight against COVID-19. This new vaccine is more targeted than the original, and it has shown promise in early clinical trials. If the vaccine is successful in Phase 2 and Phase 3 trials, it could provide even better protection against COVID-19, including emerging variants.
What does this mean for Americans?
If mRNA-1283 is successful in clinical trials and approved by the FDA, it could provide Americans with a more effective and durable COVID-19 vaccine. The new vaccine is more targeted than the original, and it has shown promise against a variety of variants, including Omicron.
The development of mRNA-1283 is also good news for the global fight against COVID-19. If the vaccine is successful, it could help to reduce the spread of the virus and protect people in all parts of the world.